Event Rate and Predictors of Post-Acute COVID-19 Sequalae and the Average Time to Diagnosis in General Population
=================================================================================================================

* K. John Muthuka
* M. Caleb Mutua
* M. Japheth Nzioki
* Rosemary Nabaweesi
* J. Kelly Oluoch
* K. Michael Kiptoo

## Abstract

**Background** Post- COVID-19 sequalae involves a variety of new, returning or ongoing symptoms that people *experience more than four weeks after* getting COVID-19. The aims of this meta-analysis were to assess the prevalence of Post-Acute COVID-19 sequalae and estimate the average time to its diagnosis; and meta-regress for possible moderators.

**Methods** A standard search strategy was used in PubMed, and then later modified according to each specific database. Search terms included “long COVID-19 or post-acute COVID-19 syndrome/sequalae”. The criteria for inclusion were published clinical articles reporting the long COVID-19, further, the average time to diagnosis of post-acute COVID-19 sequelae among primary infected patients with COVID-19. Random-effects model was used. Rank Correlation and Egger’s tests were used to ascertain publication bias. Sub-group, sensitivity and meta-regression analysis were conducted. A 95% confidence intervals were presented and a p-value < 0.05 was considered statistically significant. Review Manager 5.4 and comprehensive meta-analysis version 4 (CMA V4) were used for the analysis. The trial was PROSPERO registered (CRD42022328509).

**Results** Prevalence of post-acute COVID-19 sequalae was 42.5% (95% confidence interval (CI) 36 % to 49.3%). The PACS event rates’ range was 25 % at four months and 66 % at two months and mostly, signs and symptoms of PASC were experienced at three (54.3%, P < 0.0001) to six months (57%, P < 0.0001), further increasing at 12 months (57.9%, P= 0.0148). At an average of two months, however with the highest event rate (66%), it was not significantly associated with PACS diagnosis (P=0.08). On meta-regression, comorbidities collectively contributed to 14% of PACS with a non-significant correlation (Q = 7.05, df = 8, p = 0.5313) (R2=0.14). A cardiovascular disorder especially hypertension as a stand-alone, showed an event rate of 32% and significantly associated with PACS, 0.322 (95% CI 0.166, 0.532) (P < 0.001). Chronic obstructive pulmonary disorder (COPD) and abnormal basal metabolic index (BMI) had higher event rates of PACS (59.8 % and 55.9 %) respectively, with a non-significant correlation (P > 0.05). With a significant association, hospital re-admission contributed to 17% (Q = 8.70, df = 1, p = 0.0032) (R2= 0.17) and the study design 26% (Q = 14.32, df = 3, p = 0.0025) (R2=0.26). All the covariates explained at least some of the variance in effect size on PACS at 53% (Q = 38.81, df = 19, p = 0.0047) (R2 analog = 0.53).

**Conclusion** The prevalence of PACS in general population was 42.5%, of which cardiovascular disorders were highly linked with it with COPD and abnormal BMI also being possible conditions found in patients with PACS. Hospital re-admission predicted highly, an experience of PACS as well as prospective study design. Clinical and methodological characteristics in a specific study contributed to over 50% of PACS events. The PACS event rates ranged between 25 % at four months and 66 % at two months with most signs and symptoms experienced between three to six months increasing at 12 months.

## Introduction

Post-acute sequelae of COVID-19, also known as “long COVID,” is used to describe the long-term symptoms that might be experienced weeks to months after primary infection with SARS-CoV-2, the virus that causes COVID-19 1. Recent literature suggests that, the syndrome is described by a diverse set of symptoms that persist after a diagnosed COVID-19 infection2. This post-acute infection represents a significant challenge for patients, physicians, and society because the causes, patient profile, and even symptom patterns remain difficult to characterize3. It may include memory loss, gastrointestinal (GI) distress, fatigue, anosmia, shortness of breath, and other symptoms. PASC has been associated with acute disease severity4, further, it is suspected to be related to autoimmune factors5, as well as unresolved viral fragments6. Post-COVID conditions are found more often in people who had severe COVID-19 illness, but anyone who has been infected with the virus that causes COVID-19 can experience post-COVID conditions, even people who had mild illness or no symptoms from COVID-197. There is no test to diagnose post-COVID conditions, and people may have a wide variety of symptoms that could come from other health problems. This can make it difficult for healthcare providers to recognize post-COVID conditions. Diagnosis is considered based on health history, including if you had a diagnosis of COVID-19 either by a positive test or by symptoms or exposure, as well as doing a health examination8–10. Long COVID may be due to persistent immune disturbances11.

Studies of patients who have recovered from SARS-CoV-2 infection but have persistent symptoms have ranged widely in size, quality, and methodology, leading to confusion about the prevalence and types of persistent symptoms12. SARS-CoV-2 can produce short/long-term sequelae and reports describing post-acute COVID-19 syndrome (PACS) in the general population are increasing, however limited by lack of proper pooled average time estimation for diagnosis or occurrence. Therefore, this review aimed at assessing the prevalence and factors associated with PACS in our cohort of general population.

## Methods

A standard search strategy was used in PubMed, and then later modified according to each specific database to get the best relevant results. These included MEDLINE indexed journals; PubMed Central; NCBI Bookshelf and publishers’ Web sites. The language was restricted to English and the search dates were for studies conducted/published between June 2021 and August 2022. The basic search strategy was built based on the research question formulation (i.e., PICO or PICOS)13. They were constructed to include free-text terms (e.g., in the title and abstract) and any appropriate subject indexing (e.g., MeSH) expected to retrieve eligible studies, with the help of an expert in the review topic field or an information specialist. The summary of search terms was; long COVID-19; long COVID-19 syndrome; post-Corona Virus syndrome; Post-acute COVID-19 sequelae; Post-acute COVID-19 syndrome; Post-acute COVID-19 condition. Because the study for this topic would be limited, the outcome term (long COVID-19) in the search term was not be included initially in order to capture more studies. Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement.14 was used. All identified article titles and abstracts were screened independently by two authors (JKM, JMN), with those meeting the inclusion criteria screened further by full text review. On occasions when it was not clear from the abstract if studies were of relevance, the full text of the article was reviewed. Unanimous consensus was met on the inclusion of proposed studies for full text review among the authors (JKM, JMN, KO and CM). Full text studies were further evaluated against the inclusion and exclusion criteria. The reference lists of included studies were reviewed to ensure no other relevant studies were overlooked.

### Search terms and criteria for inclusion

Search terms included for PubMed was as follows: (long COVID-19; long COVID-19 syndrome; post-Corona Virus syndrome; Post-acute COVID-19 sequelae; Post-acute COVID-19 syndrome; Post-acute COVID-19 condition) AND (“the study” [Publication Type] OR “study as the topic” [MeSH Terms] OR “study” AND [All Fields]). A search limit for articles published from mid-2020 applied. The criteria for inclusion were published research articles reporting: 1) the rate prevalence of post-acute COVID-19 syndrome (at admission or following admission) in general population 2) the possible associated clinical parameters. Studies were excluded if they were case reports, review articles, conference abstracts, non-clinical studies, or were not available in the English language.

### Data extraction

The included studies were evaluated for the authors, year of publication/ the study was conducted, title, where it was conducted, study design (prospective, retrospective or other), age and sex of patients, number of patients, number of post-acute COVID-19 sequalae and the time of diagnosis of post-acute COVID-19 sequalae (on admission or following admission with mean/ average time to diagnosis in months). A post-acute COVID-19 sequalae case was defined as the illness that occurs in people who have a history of probable or confirmed SARS-CoV-2 infection; usually within three months from the onset of COVID-19, with symptoms and effects that last for at least two months.

### Outcome measures

The primary objectives were to report the prevalence of post-acute COVID-19 sequalae using the most recent data, post-acute COVID-19 sequalae in PLWH as from mid-2020, the associated event rate of mortality with post-acute COVID-19 sequalae, average time of acquiring/being diagnosed with post-acute COVID-19 sequalae. Secondary objectives included meta-regressing for any possible and predetermined covariates to ascertain of any relationship with post-acute COVID-19 sequalae.

### Quality assessment

Using the NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies15, all included publications were reviewed independently for potential risk of bias by two authors (JKM, JMN). The assessment tool uses 14 questions to enable allocation of a score to each article (poor, fair, or good). If there was disagreement regarding the scoring of a study, consensus was met after discussion among both assessors.

### Statistical analysis

Simple descriptive analysis was performed for the five aims of the review. Heterogeneity among the studies was assessed using the chi-squared test and I2, however due to suspected variation among the studies and associated heterogeneity random effects models were used for all meta analyses16.Post-acute COVID-19 events rates were estimated using random-effects model, the mortality associated with post-acute COVID-19 sequalae was statistically assessed using random effects models (DerSimonian and Laird)17, and event rates (ER) were presented. Publication bias was assessed using Begg and Mazumdar Rank Correlation Test and the Egger’s Test of the Intercept and a precision funnel plot was used to ascertain this the publication bias status. To account for any possible heterogeneity (I2), sub-group and sensitivity analysis were conducted and in this, some analysis used fixed-effect model analysis, further to these, meta-regression analysis was run for specific pre-determined covariates. For each outcome variable, 95% confidence intervals (CIs) were presented. A p-value < 0.05 was considered statistically significant. The meta-analysis and meta-regression was conducted using Review Manager 5.4 (Cochrane Collaboration, Oxford, UK)18 and comprehensive meta-analysis version 4 (CMA v4).

## Results

There were 2197 articles identified in the initial search of databases and reference lists *(Figure 1)*. After initial screening of titles and abstracts 197 articles met the inclusion criteria for review. On full text screening, the number reduced to 57 studies. Further, 14 studies without clinical outcomes were eliminated. A list of the 43 studies 1,4,27–36,19,37–46,20,47–56,21,57–62,22–26 that met the inclusion criteria are illustrated in *Table I*.

View this table:
[Table 1:](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/T1)

Table 1: Summer of the studies used in the analysis

![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2023/02/23/2023.02.23.23286336/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/F1)

Figure 1: 
Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram for the studies identified and included in the review.

### Prevalence of Post-Acute COVID-19 Sequelae in general population

A total of 43 studies 1,4,27–36,19,37–46,20,47–56,21,57–62,22–26 (n= 367236) reported event rates of post-acute COVID-19 Sequelae (n = 183064) in general population. The prevalence of post-acute COVID-19 Sequelae ranged from 1.6% to 82%, with a mean of 42.5% (95% CI 36 % to 49.3%)[Heterogeneity: Tau2 = 0.81; Chi2 = 24108.789, df = 42 (P = 0.030); I2= 100%] *(Figure 2)*. The prediction interval (Figure 3) demonstrates the true effects size in 95% of all the comparable populations fell between 0.10 to 0.823 demonstrating that, in some populations, the event rates of PASC is at one extreme as low as 10% and as high as 82%, a fact that would necessitate a meta-regression analysis to account for possible moderators this variation reflects differences in real proportions.

![Figure 2:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2023/02/23/2023.02.23.23286336/F2.medium.gif)

[Figure 2:](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/F2)

Figure 2: 
A forest plot on Prevalence of Post-Acute COVID-19 Sequelae in general population

![Figure 3:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2023/02/23/2023.02.23.23286336/F3.medium.gif)

[Figure 3:](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/F3)

Figure 3: 
The prediction interval demonstrating the true effects size in 95% of all the comparable populations

A funnel plot of standard error and the egger’s regression intercept test indicated a possible publication bias (intercept = −7.13010, 95% confidence interval (−15.04711, 0.78691), with t=1.81881, df=41 and 1-tailed P = 0.038) *(Figure 4)*.

![Figure 4:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2023/02/23/2023.02.23.23286336/F4.medium.gif)

[Figure 4:](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/F4)

Figure 4: 
A funnel plot of standard error for publication bias assessment

Sensitivity analysis was performed to explore the impact of excluding or including studies based on sample size, methodological quality and variance on the heterogeneity obtained (I2 = 100%). This, by weight allocation for each study using the scale relative to maximum demonstrated that, all contributed between 2% to 3% of the mean event rate and heterogeneity. To further the robustness of this, sensitivity analysis by removing one study with the highest event rate (82%) 21,the new mean event rate was 41.4% (95% CI 34.9 %, 448.2%), a non-significant difference from the original 42.5 %. This showed that, the mean PACS event rate estimation was reliable as all the studies depicted a significant P-value *(Figure 5)*.

![Figure 5:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2023/02/23/2023.02.23.23286336/F5.medium.gif)

[Figure 5:](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/F5)

Figure 5: 
A sensitivity analysis forest plot on prevalence of post-Acute COVID-19 Sequelae in general population

### Average time to and association with post-acute COVID-19 sequalae

Of the 43 studies, thirty-five (35)1,4,34,35,37–44,23,45,47,48,50–52,54–57,25,58,59,61–66,26–29,31,32, had demonstrated the times at which either a symptom of PACS was feasible or PACS was diagnosed or some clinical parameters were used to ascertain a case as PACS, while eight19,21,22,24,33,36,46,60 did not have any estimated time to PACS diagnosis. Using fixed effect model, the PACS event rates’ range following sub-group analysis was between 25 % (lowest) at four months25,27,44,47 and 66 % (highest) at two months51,62. Generally, using the point estimates with a fixed effect model, the event rates of PASC was at an average of; one month,44.6%32,42, two months, 66%51,62, three months, 54.3%26,37,38,40,41,50,54,57,59, four months, 25%25,27,44,47, five months, 26%23,48,55,56, six months, 56.5%1,4,28,29,34,58, seven months, 45.1%35,61, nine months, 36.3%31,45, eleven months,49.3%63 and twelve months, 57.9%39,43,52.It was evident that, majorly COVID-19 patients developed signs and symptoms of PASC at three months as shown by nine studies (at 54.3%, P= 0.0000) 26,37,38,40,41,50,54,57,59 to six months as shown by four studies (at 57%, P= 0.000) 4,28,34,58, further up to 12 months39,43,52, PACS tends to increase up to (57.9%, P= 0.0148). At an average of two months, however with the highest event rate (66%) in two studies51,62, it was not significantly associated with PACS diagnosis (P=0.08) as indicated in the meta-analysis grid (*Table 2*).

View this table:
[Table 2:](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/T2)

Table 2: A meta-analysis grid of sub-group analysis on the average time to and association with post-acute COVID-19 sequalae incidence in general population

### Sub-group and meta-regression analysis

To account for the substantial unaccounted substantial heterogeneity, it deemed applicable to better understand whether and which study-level factors drove the measures of effect. This meta-regression analysis was on the prevalence of post-acute COVID-19 sequalae in general population and the average time to PACS diagnosis.

On the prevalence of post-Acute COVID-19 sequalae in general population, seventeen studies4,22,43–46,55,59,60,25–28,31,33,39,42, detailing a specific leading comorbidity in each study were used for the analysis to determine their association with PACS event rates. On this meta-regression collectively, the comorbidities contributed to 14% of the PACS event rates however, not significant (Q = 7.05, df = 8, p = 0.5313) (R2=0.14) *(Supp. File 1)*.

Sub-group analysis on specific comorbidity showed that, a cardiovascular disorder, especially hypertension as per the studies included was significantly associated with post-acute COVID-19 syndrome on contrary to the other conditions depicting that, the proportion of the 14% contributed by the comorbidities was majorly by a patient who had a cardiovascular disease (CVD), majorly hypertension with a stand-alone event rate of 32%, random effects model (0.322 (95% CI 0.166, 0.532) (P = 0.000); I2 = 99%). Chronic obstructive pulmonary disorder and abnormal basal metabolic index had higher event rates (59.8 % and 55.9 %), however not significantly associated with PACS (P > 0.05) *(Table 3)*.

View this table:
[Table 3:](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/T3)

Table 3: Subgroup meta-analysis grid on comorbidities relative to PACS event

Hospital re-admission on the other side contributed to 17% of the post-acute COVID-19 syndrome on meta-regression (R2 analog = 0.17), and was significantly associated (Q = 8.70, df = 1, p = 0.0032) *(Supp. File 2)*. Study design used in a specific study showed that, the coefficient for retrospective study design (Y) was −0.6815, with a 95% confidence interval of −2.5795 to 1.2165. Studies that used this design had a mean effect size 0.6815 points lower than studies which did not use this design demonstrating that, retrospective study design was probably associated with a smaller effect size on post-acute COVID-19 syndrome. However, there was a significant relationship between the study design and post-acute COVID-19 syndrome (Q = 14.32, df = 3, p = 0.0025) (R2=0.26) *(Supp. File 3)*. The study setting whether single site or multiple site did not have any effect on post-COVID-19 syndrome same case for the year a study was conducted.

Collectively, the combined impact of all covariates in the model showed that the model is able to explain at least some of the variance in effect size on post-acute COVID-19 syndrome contributing to 53% of the post-acute COVID-19 syndrome (Q = 38.81, df = 19, p = 0.0047) (R2 analog = 0.53) *(Supp. File 4)*.

## Discussion

This review, meta-analysis and meta-regression has demonstrated the prevalence of post-acute COVID-19 sequalae in general population to be 42.5% ranging between1.6% to 82%, and comorbidities contributed to 14% of the PACS event rates specifically, a cardiovascular disorder mostly hypertension which had a stand-alone event rate of 32%. Chronic obstructive pulmonary disorder and abnormal basal metabolic index had higher event rates (59.8 % and 55.9 %), however not significantly associated with PACS. Seventeen percent (17%) of the post-acute COVID-19 sequalae was found to be due to hospital re-admission. Further, there was a significant relationship between the study design and post-acute COVID-19 syndrome while study setting and year a study was conducted did not have any effect on post-COVID-19 syndrome. Generally, other covariates related to either methodological and clinical characteristics were able to explain at least some of the variance in effect size contributing to 53% of the post-acute COVID-19 syndrome.

The reported prevalence of post-acute COVID-19 sequalae in the current review and meta-analysis of 42.5% after index infection with COVID-19 infection was similar to a study that looked at global estimated pooled PASC prevalence derived from the estimates presented in 29 studies as 43%67, and primary studies also showed 44.2% reported persistent symptoms post primary infection with COVID-19 disease68, as seen in yet another, 49.2% had 3 or more symptoms of COVID-19 post primary infection69 and 41% of long COVID-19 with symptoms persisting for more than four weeks70. Further, another study, established that, 36.55% of post-acute COVID-19 sequalae occurred between 3 and 6 months and 57.00% had one or more long-COVID feature recorded during the whole 6-month period58. Similarly or close to the current findings in this study, another study71, established that, among 127 patients who had recovered from COVID-19, 52.0% had persistent symptoms while those with mild COVID-19 recorded 49.5%. Again, conforming to be within the range of post-acute-COVID-19 syndrome in this study (1.6% to 82 %), another study established the prevalence of post-COVID-19 to be 72.6% and 46.2% for hospitalized and non-hospitalized patients, respectively72.

On comorbidities commensurate with this current finding, cardiovascular disease (CVD) emerged as a risk factor for the post-acute COVID-19 syndrome, which can affect up to 54% of patients who recover from the acute infection73, substantiated further by findings that, presence of certain chronic condition is linked with post-acute COVID-19 sequalae74. On the other hand, as found in this study at an event rate of 60 % though not significantly associated with PACS, chronic obstructive pulmonary disorder was found to be among comorbidities associated with long COVID-19 presenting with chronic fatigue (1.68, 1.21 to 2.32)75, and again regarding chronic obstructive pulmonary disorder and abnormal basal metabolic index, a study established that, high BMI and previous pulmonary disease could be risk factors for post-acute COVID-19 (long COVID-19) development76, further on basal metabolic index, a study concludes that, long COVID is more likely to occur in people with a higher body mass index (BMI)77. Like in this study subject to comorbidities generally predicting post-acute COVID-19 sequalae at 14 % (R2=0.14), another study established overall severity of comorbidities as one the strongest risk factors for post-acute COVID-19 sequelea72. Hospital re-admission contributing to over 17 % of post-acute COVID-19 sequalae as per this study, similar findings have shown some consistency where patients (19.9%) who survived COVID-19 hospitalization were readmitted78, and another, the readmission rate was 13.3%79.

This study reported COVID-19 patients developed signs and symptoms post-acute COVID-19 syndrome at three months (at 54.3%) to six months (at 57%) which tended to increase up to 12 months (57.9%). Similar or close to these findings, another study established that, at 3 months of follow-up, 66·7%) of participants reported new or persistent COVID-19-related symptoms50 and another that, hospitalized and non-hospitalized patients with confirmed or suspected COVID-19, multiple symptoms are present about 3 months after symptoms onset80. A forty-five per cent (45%) of health care workers also reported persistent symptoms at three to four months81. As regards post COVID-19 sequalae at six months (6-months), a previous study shows post-acute COVID-19 sequalae prevalence was 50% in adults at 6Lmonths82, close to the 54% in the current findings. At 12 months, post-acute COVID-19 sequalae was reported as (50%) ≥1 PASC symptom, close to 58% as per the current findings. This is further substantiated by the findings in a study that, Persistent symptoms were highly prevalent, especially fatigue, shortness of breath, headache, brain fog/confusion, and altered taste/smell, which persisted beyond 1 year (12 months) among 56%83. Contrary to the current findings though, some studies have reported a decreasing post-acute COVID-19 sequalae from sixth to twelfth month 1,82

A limitation of the current review was the defined inclusion criteria for a post-acute COVID-19 sequalae patient, presenting with either one or more suspected signs and symptoms depicting the syndrome. This may have resulted in diverse estimate of the prevalence of post – acute COVID-19 during different times to event which were also estimated on an average basis. However, the majority of studies in the current review included a clearly mentioned post-acute COVID-19 sequalae either as persistent symptoms after primary infection with COVID-19 or a cluster of signs and symptoms post recovery from the index infection with COVID-19. Further, the review focused only on the post-acute COVID-19 sequalae devoid categorizing it as per the time a patient experienced the same. This, was even though not very important as the authors intended to ascertain the prevalence and any association with subject variable, plus, a meta-regression was performed to ensure such differential aspects were taken care of.

## Data Availability

All data produced in the present work are contained in the manuscript

## Author contributions

**J.K.M:** Designed the study, reviewed and analyzed the data, participated in quality assessment process, Wrote and submitted the manuscript.

**C.M.M:** Reviewed studies and participated in quality assessment process.

**J.N.M:** Reviewed and analyzed the data, Edited the manuscript.

**J.K.O:** Participated in quality assessment process, Edited the manuscript.

**R.M.N:** Reviewed the studies, participated in quality assessment process, Proofread the manuscript

**M.K.K:** Participated in quality assessment, Edited the manuscript.

## Funding statement

No benefits in any form have been received or was received from a commercial party related directly or indirectly to the subject of this article.

## Ethical review statement

No ethical approval was required for this study.

## Study’s Supplementary Files

View this table:
[Supp. File 1](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/T4)

Supp. File 1 

View this table:
[Supp. File 2](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/T5)

Supp. File 2 

View this table:
[Supp. File 3](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/T6)

Supp. File 3 

View this table:
[Supp. File 4](http://medrxiv.org/content/early/2023/02/23/2023.02.23.23286336/T7)

Supp. File 4 

*   Received February 23, 2023.
*   Revision received February 23, 2023.
*   Accepted February 23, 2023.


*   © 2023, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270). doi:10.1016/S0140-6736(20)32656-8
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)32656-8&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

2.  2.Wijeratne T, Crewther S. Post-COVID 19 Neurological Syndrome (PCNS); a novel syndrome with challenges for the global neurology community. J Neurol Sci. 2020;419. doi:10.1016/j.jns.2020.117179
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jns.2020.117179&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

3.  3.Rando HM, Bennett TD, Byrd JB, et al. Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information. medRxiv Prepr Serv Heal Sci. Published online 2021. doi:10.1101/2021.03.20.21253896
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyMS4wMy4yMC4yMTI1Mzg5NnYxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDIvMjMvMjAyMy4wMi4yMy4yMzI4NjMzNi5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

4.  4.Blomberg B, Mohn KGI, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27(9). doi:10.1038/s41591-021-01433-3
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41591-021-01433-3&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34163090&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

5.  5.Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8). doi:10.1038/s41584-020-0448-7
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41584-020-0448-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

6.  6.Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.686029
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3389/fimmu.2021.686029&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34276671&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

7.  7.Vu T, McGill SC. An Overview of Post–COVID-19 Condition (Long COVID). Can J Heal Technol. 2021;1(9). doi:10.51731/cjht.2021.160
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.51731/cjht.2021.160&link_type=DOI) 

8.  8.Crook H, Raza S, Nowell J, Young M, Edison P. Long covid - Mechanisms, risk factors, and management. BMJ. 2021;374. doi:10.1136/bmj.n1648
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNzQvanVsMjZfMS9uMTY0OCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzAyLzIzLzIwMjMuMDIuMjMuMjMyODYzMzYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

9.  9.Mumoli N, Conte G, Evangelista I, Cei M, Mazzone A, Colombo A. Post-COVID or long-COVID: Two different conditions or the same? J Infect Public Health. 2021;14(10). doi:10.1016/j.jiph.2021.08.019
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jiph.2021.08.019&link_type=DOI) 

10. 10.Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021;75(3). doi:10.1111/ijcp.13746
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/ijcp.13746&link_type=DOI) 

11. 11.Ryan FJ, Hope CM, Masavuli MG, et al. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. 2022;20(1). doi:10.1186/s12916-021-02228-6
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12916-021-02228-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35027067&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

12. 12.Garg M, Maralakunte M, Garg S, et al. The conundrum of ‘long-covid-19L: A narrative review. Int J Gen Med. 2021;14. doi:10.2147/IJGM.S316708
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2147/IJGM.S316708&link_type=DOI) 

13. 13.Tawfik GM, Dila KAS, Mohamed MYF, et al. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 2019;47(1). doi:10.1186/s41182-019-0165-6
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s41182-019-0165-6&link_type=DOI) 

14. 14.Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372. doi:10.1136/bmj.n71
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE1OiIzNzIvbWFyMjlfMi9uNzEiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMy8wMi8yMy8yMDIzLjAyLjIzLjIzMjg2MzM2LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

15. 15.Bagias C, Sukumar N, Weldeselassie Y, Oyebode O, Saravanan P. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. Int J Environ Res Public Health. 2021;18(4).
    
    

16. 16.Schreck N, Piepho HP, Schlather M. Best prediction of the additive genomic variance in random-effects models. Genetics. 2019;213(2). doi:10.1534/genetics.119.302324
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiZ2VuZXRpY3MiO3M6NToicmVzaWQiO3M6OToiMjEzLzIvMzc5IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDIvMjMvMjAyMy4wMi4yMy4yMzI4NjMzNi5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

17. 17.Suurmond R, van Rhee H, Hak T. Introduction, comparison, and validation of Meta-Essentials: A free and simple tool for meta-analysis. Res Synth Methods. 2017;8(4). doi:10.1002/jrsm.1260
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jrsm.1260&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28801932&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

18. 18.Cochrane. Review Manager (RevMan) [Computer program]. Version 5.4. Copenhagen: The Nordic Cochrane Centre. Cochrane Collab. Published online 2020.
    
    

19. 19.Goel N, Goyal N, Kumar R. Clinico-radiological evaluation of post COVID-19 at a tertiary pulmonary care centre in Delhi, India. Monaldi Arch chest Dis = Arch Monaldi per le Mal del torace. 2021;91(3). doi:10.4081/monaldi.2021.1682
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.4081/monaldi.2021.1682&link_type=DOI) 

20. 20.Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223). doi:10.1016/S0140-6736(20)30183-5
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)30183-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31986264&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

21. 21.Wanga V, Chevinsky JR, Dimitrov L V., et al. Long-Term Symptoms Among Adults Tested for SARS-CoV-2 — United States, January 2020-April 2021. MMWR Recomm Reports. 2021;70(36). doi:10.15585/mmwr.mm7036a1
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.15585/mmwr.mm7036a1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34499626&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

22. 22.Somani SS, Richter F, Fuster V, et al. Characterization of Patients Who Return to Hospital Following Discharge from Hospitalization for COVID-19. J Gen Intern Med. 2020;35(10). doi:10.1007/s11606-020-06120-6
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s11606-020-06120-6&link_type=DOI) 

23. 23.Perlis RH, Green J, Santillana M, et al. Persistence of symptoms up to 10 months following acute COVID-19 illness. medRxiv Prepr Serv Heal Sci. Published online 2021. doi:10.1101/2021.03.07.21253072
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyMS4wMy4wNy4yMTI1MzA3MnYxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDIvMjMvMjAyMy4wMi4yMy4yMzI4NjMzNi5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

24. 24.Leijte WT, Wagemaker NMM, van Kraaij TDA, et al. [Mortality and re-admission after hospitalization with COVID-19]. Ned Tijdschr Geneeskd. 2020;164.
    
    

25. 25.Pinato DJ, Tabernero J, Bower M, et al. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol. 2021;22(12). doi:10.1016/S1470-2045(21)00573-8
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1470-2045(21)00573-8&link_type=DOI) 

26. 26. P. S, Madhavan S, Pandurangan V. Prevalence, Pattern and Functional Outcome of Post COVID-19 Syndrome in Older Adults. Cureus. Published online 2021. doi:10.7759/cureus.17189
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7759/cureus.17189&link_type=DOI) 

27. 27.Guarin G, Lo KB, Bhargav R, et al. Factors associated with hospital readmissions among patients with COVID-19: A single-center experience. J Med Virol. 2021;93(9). doi:10.1002/jmv.27104
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.27104&link_type=DOI) 

28. 28.Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in Adults at 6 Months after COVID-19 Infection. JAMA Netw Open. 2021;4(2). doi:10.1001/jamanetworkopen.2021.0830
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamanetworkopen.2021.0830&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33606031&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

29. 29.Günster C, Busse R, Spoden M, et al. 6-month mortality and readmissions of hospitalized COVID-19 patients: A nationwide cohort study of 8,679 patients in Germany. PLoS One. 2021;16(8 August). doi:10.1371/journal.pone.0255427
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0255427&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34351975&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

30. 30.Fernández-de-las-Peñas C, Guijarro C, Plaza-Canteli S, Hernández-Barrera V, Torres-Macho J. Prevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study. Lung. 2021;199(3). doi:10.1007/s00408-021-00450-w
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00408-021-00450-w&link_type=DOI) 

31. 31.Zayet S, Zahra H, Royer PY, et al. Post-COVID-19 syndrome: Nine months after SARS-CoV-2 infection in a cohort of 354 patients: Data from the first wave of COVID-19 in nord franche-comté hospital, France. Microorganisms. 2021;9(8). doi:10.3390/microorganisms9081719
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/microorganisms9081719&link_type=DOI) 

32. 32.Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post–COVID-19 interstitial lung disease: An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18(5). doi:10.1513/AnnalsATS.202008-1002OC
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1513/AnnalsATS.202008-1002OC&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33433263&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

33. 33.Naik S, Haldar SN, Soneja M, et al. Post COVID-19 sequelae: A prospective observational study from Northern India. Drug Discov Ther. 2021;15(5). doi:10.5582/ddt.2021.01093
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.5582/ddt.2021.01093&link_type=DOI) 

34. 34.Peghin M, Palese A, Venturini M, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021;27(10). doi:10.1016/j.cmi.2021.05.033
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cmi.2021.05.033&link_type=DOI) 

35. 35.Menges D, Ballouz T, Anagnostopoulos A, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS One. 2021;16(7 July). doi:10.1371/journal.pone.0254523
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0254523&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34252157&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

36. 36.Mahmud R, Rahman MM, Rassel MA, et al. Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh. PLoS One. 2021;16(4 April). doi:10.1371/journal.pone.0249644
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0249644&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

37. 37.Khodeir MM, Shabana HA, Rasheed Z, et al. COVID-19: Post-recovery long-term symptoms among patients in Saudi Arabia. PLoS One. 2021;16(12 December). doi:10.1371/journal.pone.0260259
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0260259&link_type=DOI) 

38. 38.Kayaaslan B, Eser F, Kalem AK, et al. Post-COVID syndrome: A single-center questionnaire study on 1007 participants recovered from COVID-19. J Med Virol. 2021;93(12). doi:10.1002/jmv.27198
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.27198&link_type=DOI) 

39. 39.Maestre-Muñiz MM, Arias Á, Mata-Vázquez E, et al. Long-term outcomes of patients with coronavirus disease 2019 at one year after hospital discharge. J Clin Med. 2021;10(13). doi:10.3390/jcm10132945
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/jcm10132945&link_type=DOI) 

40. 40.Moreno-Pérez O, Merino E, Leon-Ramirez JM, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021;82(3). doi:10.1016/j.jinf.2021.01.004
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jinf.2021.01.004&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33450302&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

41. 41.Venturelli S, Benatti S V., Casati M, et al. Surviving COVID-19 in Bergamo Province: A post-Acute outpatient re-evaluation. Epidemiol Infect. Published online 2021. doi:10.1017/S0950268821000145
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1017/S0950268821000145&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

42. 42.Hirschtick JL, Titus AR, Slocum E, et al. Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics. Clin Infect Dis. 2021;73(11). doi:10.1093/cid/ciab408
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciab408&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34007978&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

43. 43.Boscolo-Rizzo P, Guida F, Polesel J, et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. 2021;11(12). doi:10.1002/alr.22832
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/alr.22832&link_type=DOI) 

44. 44.Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands: A Longitudinal Study among Nonhospitalized Patients. Clin Infect Dis. 2021;73(11). doi:10.1093/cid/ciaa1792
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciaa1792&link_type=DOI) 

45. 45.Elkan M, Dvir A, Zaidenstein R, et al. Patient-reported outcome measures after hospitalization during the covid-19 pandemic: A survey among covid-19 and non-covid-19 patients. Int J Gen Med. 2021;14. doi:10.2147/IJGM.S323316
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2147/IJGM.S323316&link_type=DOI) 

46. 46.Maamar M, Artime A, Pariente E, et al. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin. 2022;38(6). doi:10.1080/03007995.2022.2042991
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/03007995.2022.2042991&link_type=DOI) 

47. 47.Tleyjeh IM, Saddik B, AlSwaidan N, et al. Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up. PLoS One. 2021;16(12 December). doi:10.1371/journal.pone.0260568
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0260568&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

48. 48.Ogoina D, James HI, Ogoinja SZ. Post-discharge symptoms among hospitalized covid-19 patients in Nigeria: A single-center study. Am J Trop Med Hyg. 2021;105(3). doi:10.4269/ajtmh.21-0509
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.4269/ajtmh.21-0509&link_type=DOI) 

49. 49.Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821). doi:10.1038/s41586-020-2588-y
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41586-020-2588-y&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32717743&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

50. 50.Dryden MTG, Mudara C, Vika C, et al. Post COVID-19 Condition in South Africa: 3-Month Follow-Up after Hospitalisation with SARS-CoV-2. SSRN Electron J. Published online 2022. doi:10.2139/ssrn.4007183
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2139/ssrn.4007183&link_type=DOI) 

51. 51.Bell ML, Catalfamo CJ, Farland L V., et al. Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. PLoS One. 2021;16(8 August). doi:10.1371/journal.pone.0254347
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0254347&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34347785&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

52. 52.Becker C, Beck K, Zumbrunn S, et al. Long COVID 1 year after hospitalisation for COVID-19: a prospective bicentric cohort study. Swiss Med Wkly. 2021;151(41-42). doi:10.4414/SMW.2021.W30091
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.4414/SMW.2021.W30091&link_type=DOI) 

53. 53.Wang G, Cao K, Liu K, et al. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells. Cell Death Differ. 2018;25(7). doi:10.1038/s41418-017-0006-2
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41418-017-0006-2&link_type=DOI) 

54. 54.Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: Results from a prospective UK cohort. Thorax. 2021;76(4). doi:10.1136/thoraxjnl-2020-216086
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToidGhvcmF4am5sIjtzOjU6InJlc2lkIjtzOjg6Ijc2LzQvMzk5IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDIvMjMvMjAyMy4wMi4yMy4yMzI4NjMzNi5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

55. 55.Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: Retrospective cohort study. BMJ. 2021;372. doi:10.1136/bmj.n693
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNzIvbWFyMzFfMTAvbjY5MyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzAyLzIzLzIwMjMuMDIuMjMuMjMyODYzMzYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

56. 56.Osikomaiya B, Erinoso O, Wright KO, et al. ‘Long COVID’: persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis. 2021;21(1). doi:10.1186/s12879-020-05716-x
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12879-020-05716-x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33765941&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

57. 57.Sigfrid L, Drake TM, Pauley E, et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Reg Heal - Eur. 2021;8. doi:10.1016/j.lanepe.2021.100186
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.lanepe.2021.100186&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34386785&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

58. 58.Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9). doi:10.1371/journal.pmed.1003773
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pmed.1003773&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

59. 59.Wynberg E, van Willigen HDG, Dijkstra M, et al. Evolution of Coronavirus Disease 2019 (COVID-19) Symptoms During the First 12 Months After Illness Onset. Clin Infect Dis. 2022;75(1). doi:10.1093/cid/ciab759
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciab759&link_type=DOI) 

60. 60.Osmanov IM, Spiridonova E, Bobkova P, et al. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. Eur Respir J. 2022;59(2). doi:10.1183/13993003.01341-2021
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiZXJqIjtzOjU6InJlc2lkIjtzOjEyOiI1OS8yLzIxMDEzNDEiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMy8wMi8yMy8yMDIzLjAyLjIzLjIzMjg2MzM2LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

61. 61.Pereira C, Harris BHL, Di Giovannantonio M, et al. The Association Between Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Post-COVID-19 Syndrome in Healthcare Workers. J Infect Dis. 2021;223(10). doi:10.1093/infdis/jiab120
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiab120&link_type=DOI) 

62. 62.Abdelrahman MM, Abd-Elrahman NM, Bakheet TM. Persistence of symptoms after improvement of acute COVID19 infection, a longitudinal study. J Med Virol. 2021;93(10). doi:10.1002/jmv.27156
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.27156&link_type=DOI) 

63. 63.Fernández-De-las-peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Cuadrado ML, Florencio LL. Defining post-covid symptoms (Post-acute covid, long covid, persistent post-covid): An integrative classification. Int J Environ Res Public Health. 2021;18(5). doi:10.3390/ijerph18052621
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/ijerph18052621&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

64. 64.Vinhaes CL, Araujo-Pereira M, Tibúrcio R, et al. Systemic inflammation associated with immune reconstitution inflammatory syndrome in persons living with hiv. Life. 2021;11(1). doi:10.3390/life11010065
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/life11010065&link_type=DOI) 

65. 65.Wang W, Liu X, Wu S, et al. Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients with Pneumonia: Analysis of Disease Characteristics. J Infect Dis. 2020;222(9). doi:10.1093/infdis/jiaa387
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiaa387&link_type=DOI) 

66. 66.King CG, Guyette RW, Piotrowski C. Online exams and cheating: An empirical analysis of business students’ views. J Educ Online. 2009;6(1). doi:10.9743/JEO.2009.1.5
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.9743/JEO.2009.1.5&link_type=DOI) 

67. 67.Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Acute Sequelae of COVID-19 (PASC) or Long COVID: A Meta-Analysis and Systematic Review. medRxiv. 2021;2019.
    
    

68. 68.Kingery JR, Safford MM, Martin P, et al. Health Status, Persistent Symptoms, and Effort Intolerance One Year After Acute COVID-19 Infection. J Gen Intern Med. 2022;37(5). doi:10.1007/s11606-021-07379-z
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s11606-021-07379-z&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

69. 69.Fortini A, Torrigiani A, Sbaragli S, et al. COVID-19: persistence of symptoms and lung alterations after 3–6 months from hospital discharge. Infection. 2021;49(5). doi:10.1007/s15010-021-01638-1
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s15010-021-01638-1&link_type=DOI) 

70. 70.ONS. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 2 December 2021. Office for National Statistics.
    
    

71. 71.Sugiyama A, Miwata K, Kitahara Y, et al. Long COVID occurrence in COVID-19 survivors. Sci Rep. 2022;12(1). doi:10.1038/s41598-022-10051-z
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41598-022-10051-z&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35411017&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

72. 72.Förster C, Colombo MG, Wetzel AJ, Martus P, Joos S. Persisting Symptoms after COVID-19: Prevalence and Risk Factors in a Population-Based Cohort. Dtsch Arztebl Int. 2022;119(10). doi:10.3238/arztebl.m2022.0147
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3238/arztebl.m2022.0147&link_type=DOI) 

73. 73.Groff D, Sun A, Ssentongo AE, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw Open. 2021;4(10). doi:10.1001/jamanetworkopen.2021.28568
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamanetworkopen.2021.28568&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34643720&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

74. 74.Lavery AM, Preston LE, Ko JY, et al. Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission — United States, March– August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(45). doi:10.15585/mmwr.mm6945e2
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.15585/mmwr.mm6945e2&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33180754&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

75. 75.Munblit D, Bobkova P, Spiridonova E, et al. Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study. medRxiv. Published online 2021. doi:10.1101/2021.02.17.21251895
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyMS4wMi4xNy4yMTI1MTg5NXYxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDIvMjMvMjAyMy4wMi4yMy4yMzI4NjMzNi5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

76. 76.Vimercati L, De Maria L, Quarato M, et al. Association between long COVID and overweight/obesity. J Clin Med. 2021;10(18). doi:10.3390/jcm10184143
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/jcm10184143&link_type=DOI) 

77. 77.Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv. Published online 2020.
    
    

78. 78.Donnelly JP, Wang XQ, Iwashyna TJ, Prescott HC. Readmission and Death after Initial Hospital Discharge among Patients with COVID-19 in a Large Multihospital System. JAMA - J Am Med Assoc. 2021;325(3). doi:10.1001/jama.2020.21465
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.21465&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33315057&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F02%2F23%2F2023.02.23.23286336.atom) 

79. 79.Fukushima EA, Santos CV, Sharma M, Szpunar SM, Saravolatz L, Bhargava A. 36. Clinical Features of and Risk Factors for 30-day Readmission after an Initial Hospitalization with COVID-19. Open Forum Infect Dis. 2021;8(Supplement_1). doi:10.1093/ofid/ofab466.036
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ofid/ofab466.036&link_type=DOI) 

80. 80.Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4). doi:10.1183/23120541.00542-2020
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NToiZXJqb3IiO3M6NToicmVzaWQiO3M6MTQ6IjYvNC8wMDU0Mi0yMDIwIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDIvMjMvMjAyMy4wMi4yMy4yMzI4NjMzNi5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

81. 81.Gaber TAZK, Ashish A, Unsworth A. Persistent post-covid symptoms in healthcare workers. Occup Med (Chic Ill). 2021;71(3). doi:10.1093/occmed/kqab043
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/occmed/kqab043&link_type=DOI) 

82. 82.Pazukhina E, Andreeva M, Spiridonova E, et al. Prevalence and Risk Factors of Post-COVID-19 Condition in Adults and Children at 6 and 12 Months After Hospital Discharge: A Prospective, Cohort Study in Moscow (Stop COVID). SSRN Electron J. Published online 2022. doi:10.2139/ssrn.4020142
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2139/ssrn.4020142&link_type=DOI) 

83. 83.Durstenfeld MS, Sun K, Ma Y, et al. Association of HIV with COVID-19 Outcomes Among Hospitalized Adults. medRxiv. Published online 2021.